The Listed Company Roadshow of the 10th China Pharmaceutical Innovation and Investment Conference (CBIIC) was successfully held on the afternoon of October 26 and the morning of October 27 in Nanjing Jiangbei New Area. As an annual flagship event in the pharmaceutical industry, this roadshow brought together 17 leading companies listed on major global capital markets, including the Shanghai Stock Exchange, Shenzhen Stock Exchange, Hong Kong Stock Exchange, and Nasdaq. Through in-depth presentations and industry dialogue, participants explored trends in pharmaceutical innovation and jointly discussed pathways toward high-quality industry development.

The two sessions of the Listed Company Roadshow were respectively moderated by TAN Guochao, Deputy Director & Chief Analyst of Huaan Securities Research Institute, and LI Yun, Asia Head of BD Deals at SAI MedPartners.

On the afternoon of October 26, LI Yuanpei, Asia Head of MA & Evidence Generation of SAI MedPartners, delivered a keynote speech titled “China Pharmaceutical Innovation Evaluation Framework and Exploration” The presentation systematically introduced China’s pharmaceutical innovation policy landscape, the current status of R&D and regulatory review and approval, global evaluation practices, and localized implementation approaches. It aims to establish an evaluation system that aligns with international standards while incorporating Chinese characteristics, enabling scientific and impartial assessment of innovation capabilities of Chinese pharmaceutical companies, enhancing their global influence, and promoting high-quality development of China’s pharmaceutical innovation.

On the morning of October 27, CHI Yongsheng, Secretary-General of the Institute for Global Securities Market at Tsinghua University, delivered a keynote speech titled “Leveraging Market Value Management to Enhance the Investment Value of Healthcare Organizations.” In his speech, he reviewed the evolution of China’s market value management policies from initial exploration to comprehensive implementation, and provided in-depth analysis of the current macroeconomic environment and capital market trends in the healthcare and life sciences industry. He emphasized that listed companies should shift from traditional mindsets and regard market value growth as a strategic, systematic undertaking rooted in intrinsic corporate value and requiring organization-wide participation. He further suggested that companies should seize the opportunities presented in the “15th Five-Year Plan” period by deeply integrating technological innovation, industrial innovation, ESG principles, and data assets to systematically enhance investment value, enabling market capitalization growth from tens of billions to hundreds of billions, and even trillions.

A total of 17 representatives from listed companies, including Sciwind Biosciences, CStone Pharmaceuticals, 3SBio, Biocytogen, Jacobio Pharmaceuticals, Jiuzhou Pharmaceutical, Hengrui Medicine, JW Therapeutics, 3D Medicines, HUTCHMED, Ascentage Pharma, Frontier Biotechnologies, Betta Pharmaceuticals, TransThera, Gan & Lee Pharmaceuticals, InnoCare Pharma, and Amoy Diagnostics, delivered presentations in sequence. Their sharing focused on core corporate strengths, covering entrepreneurial journeys and key milestones, as well as team culture development, talent pipeline building, technological breakthroughs, diversified pipeline strategies, and cutting-edge R&D progress. They also provided forward-looking insights into global development strategies. The presentations, rich in substance and diverse in perspectives, not only created a multidimensional exchange of ideas but also strengthened long-term confidence among investors and partners, laying a solid foundation for future win-win collaboration.

First Row: LU Anbang, NI Weicong, ZHAO Xinyi

Second Row: WANG Yongliang, WANG Yi, XU Feng

Third Row: LIU Xiaohan, LIN Zhuangwei, XIA Fang

Fourth Row: WU Jiajun, HUANG Zhi, XIE Dong

Fifth Row: DING Shizhe, FENG Jie, SUN Cheng

Sixth Row: YUAN Bei, XUE Yaxin

A decade of dedication has yielded fruitful outcomes, with the platform continuously empowering industry advancement. Over the past ten years, the Listed Company Roadshow has evolved into one of the most influential resource-matching platforms in China’s pharmaceutical industry. It serves not only as a key channel for investors to identify high-quality projects, but also promotes deep integration across industry, academia, research, and capital through frequent and in-depth interactions. Over the decade, the platform has witnessed China’s innovative drug industry transition from a “follower” to a “parallel runner,” and in certain areas, to a “global leader,” highlighting the catalytic role of capital market opening policies in driving pharmaceutical innovation.

The successful convening of this roadshow once again demonstrates the increasing maturity and vitality of China’s pharmaceutical innovation ecosystem. Driven by the dual engines of capital and innovation, a more globally competitive pharmaceutical industry cluster is rapidly emerging. Looking ahead, the Listed Company Roadshow will continue to optimize its platform functions, focus on unmet clinical needs, support breakthrough technologies, and contribute China’s wisdom and strength to global healthcare development.